Fundamentals of stem cell mobilization for the heart: Prospects for treating heart disease

Current Opinion in Investigational Drugs

Volumn 7, Issue 9, 2006, Pages 799-805

  Rahman, Joseph E ^a   Maclellan, W Robb ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AMD 3100; Cardiovascular disease; Endothelial progenitor cell; Granulocyte colony stimulating factor; Myocardial repair; Statin; Stem cell

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); ADENOVIRUS VECTOR; ALKALINE PHOSPHATASE; CHEMOKINE RECEPTOR CXCR4; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LACTATE DEHYDROGENASE; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; STROMAL CELL DERIVED FACTOR 1;

ACUTE CORONARY SYNDROME; ADULT RESPIRATORY DISTRESS SYNDROME; ANGINA PECTORIS; BONE PAIN; CAUSE OF DEATH; CELL ISOLATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIAGNOSTIC PROCEDURE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE; HEMATOPOIETIC STEM CELL; HUMAN; HYPERURICEMIA; IN-STENT RESTENOSIS; ISCHEMIC HEART DISEASE; LEUKOCYTOSIS; MESENCHYMAL STEM CELL; MORBIDITY; MORTALITY; NONHUMAN; PLASMAPHERESIS; PROPHYLAXIS; PROTEIN PROTEIN INTERACTION; REVIEW; SICKLE CELL ANEMIA; SPLEEN RUPTURE; SPLENOMEGALY; STEM CELL; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; TISSUE REGENERATION; TISSUE REPAIR; VASCULITIS;

ANIMALS; CARDIOVASCULAR AGENTS; ENDOTHELIAL CELLS; HEART DISEASES; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HETEROCYCLIC COMPOUNDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RECEPTORS, CXCR4; RECEPTORS, GRANULOCYTE COLONY-STIMULATING FACTOR; REGENERATION;

EID: 33748669868     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Hoes AW, Mosterd A, Grobbee DE: An epidemic of heart failure? Recent evidence from Europe. Eur Heart J (1998) 19(Suppl L):L2-L9.
2. Packer M: The neurohormonal hypothesis: A theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol (1992) 20(1):248-254.
3. Pepine CJ, Feldman AM: Introduction: There is an important need for increased understanding of the pathophysiology of heart failure postinfarction, new treatment strategies, earlier implementation of effective strategies, and more effective use of existing therapies. Am J Cardiol (2006) 97(10A): 1F-3F.
4. Dimmeler S, Zeiher AM, Schneider MD. Unchain my heart: The scientific foundations of cardiac repair. J Clin Invest (2005) 115(3):572-583.
5. Anversa P, Leri A, Kajstura J: Stem cells and heart disease. In: Essentials of Stem Cell Biology. Lanza R (Ed), Elsevier Press, Boston, MA, USA (2006):425-430.
6. Oh H, Bradfute SB, Gallardo TD, Nakamura T, Gaussin V, Mishina Y, Pocius J, Michael LH, Behringer RR, Garry DJ, Entman ML, Schneider MD: Cardiac progenitor cells from adult myocardium: Homing, differentiation, and fusion after infarction. Proc Natl Acad Sci USA (2003) 100(21):12313-12318.
7. Laugwitz KL, Moretti A, Lam J, Gruber P, Chen Y, Woodard S, Lin LZ, Cai CL, Lu MM, Reth M, Platoshyn O et al. Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages. Nature (2005) 433(7026):647-653.
8. Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, Chimenti S, Kasahara H, Rota M, Musso E, Urbanek K, Leri A et al: Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell (2003) 114(6):763-776.
9. Muraglia A, Cancedda R, Quarto R. Clonal mesenchymall progenitors from human bone marrow differentiate in vitro according to a hierarchical model. J Cell Sci (2000) 113(7):1161-1166.
10. Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, Alfonso Z, Fraser JK, Benhaim P, Hedrick MH. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell (2002) 13(12):4279-4295.
11. Jiang Y, Vaessen B, Lenvik T, Blackstad M, Reyes M, Verfaillie CM. Multipotent progenitor cells can be isolated from postnatal murine bone marrow, muscle and brain. Exp Hematol (2002) 30(6):896-904.
12. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science (1999) 284(5411):143-147.
13. Makino S, Fukuda K, Miyoshi S, Konishi F, Kodama H, Pan J, Sano J, Takahashi T, Hori S, Abe H, Hata J et al: Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest 1999 103(5):697-705.
14. Wollert KC, Drexler H. Mesenchymal stem cells for myocardial infarction: Promises and pitfalls. Circulation (2005) 112(2):151-153.
15. Nagaya N, Kangawa K, ltoh T, Iwase T, Murakami S, Miyahara Y, Fujii T, Uematsu M, Ohgushi H, Yamagishi M, Tokudome T et al: Transplantation of mesenchymal stem cells improves cardiac function in a rat model of dilated cardiomyopathy. Circulation (2005) 112(8):1128-1135.
16. Murry C, Reinecke H, Pabon L: Regeneration gaps: Observations on stem cells and cardiac repair. J Am Coll Cardiol (2006) 47(9):1777-1785.
17. Mangi AA, Noiseux N, Kong D, He H, Rezvani M, Ingwall JS, Dzau VJ. Mesenchymall stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med (2003) 9(9):1195-1201.
18. Iwami Y, Masuda H, Asahara T: Endothelial progenitor cells: Past, state of the art, and future. J Cell Mol Med (2004) 8(4):488-497.
19. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM: Isolation of putative progenitor endothelial cells for angiogensis. Science (1997) 275(5302):964-967.
20. Schatteman GC, Hanlon HD, Jiao C, Dodds SG, Christy BA: Blood-derived angioblasts accelerate blood-flow restoration in diabetic mice. J Clin Invest (2000) 106(4):571-578.
21. Yeh ET, Zhang S, Wu HD, Korbling M, Willerson JT, Estrov Z: Transdifferentiation of human peripheral blood CD34+-enriched cell population into cardiomyocytes, endothelial cells and smooth muscle cells in vivo. Circulation (2003) 108(17):2070-2073.
22. Shintani S, Murohara T, Ikeda H, Ueno T, Honma T, Katoh A, Sasaki K, Shimada T, Oike Y, Imaizumi T: Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation (2001) 103(23):2776-2779.
23. Natori T, Sata M, Washida M, Hirata Y, Nagai R, Makuuchi M: G-CSF stimulates angiogenesis and promotes tumor growth: Potential contribution of bone marrow-derived endothelial progenitor cells. Biochem Biophys Res Commun (2002) 297(4):1058-1061.
24. Hill JM, Zalos G, Halcox JPJ, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T: Circulating endothelial progenitor cells, vascular function and cardiovascular risk. N Engl J Med (2003) 348(7):593-600.
25. Kunz GA, Liang G, Cuculoski F, Gregg D, Vata KC, Shaw LK, Goldschmidt-Clermont PJ, Dong C, Taylor DA, Peterson ED: Circulating endothelial progenitor cells predict coronary artery disease severity. Am Heart J (2006) 152(1):190-195.
26. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Böhm M, Nickenig G: Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med (2005) 353(10):999-1007.
27. Hagege AA, Marolleau JP, Vilquin JT, Alheritiere A, Peyrard S, Duboc D, Abergel E, Messas E, Mousseaux E, Schwartz K, Desnos M, Menasche P: Skeletal myoblast transplantation in ischemic heart failure: Long-term follow-up of the first phase I cohort of patients. Circulation (2006) 114(Suppl 1): I108-I113.
28. Dib N, Michler RE, Pagani FD, Wright S, Kereiakes DJ, Lengerich R, Binkley P, Buchele D, Anand I, Swingen C, Di Carli MF et al: Safety and feasibility of autologous myoblast transplantation in patients with ischemic cardiomyopathy: Four-year follow-up. Circulation (2005) 112(12):1748-1755.
29. Layton JE, Hall NE: The interaction of G-CSF with its receptor. Front Biosci (2006) 11:3181-3189.
30. Harada M, Qin Y, Takano H, Minamino T, Zou Y, Toko H, Ohtsuka M, Matsuura K, Sano M, Nishi J, Managa K et al: G-CSF prevents cardiac remodeling after myocardial infarction by activating the JAK-STAT pathway in cardiomyocytes. Nat Med (2005) 11(3):305-311.
31. Kocher AA, Schuster MD, Szabolcs MJ, Takuma S, Burkhoff D, Wang J, Homma S, Edwards NM, Itescu S: Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med (2001) 7(4):430-436.
32. Orlic D, Kajstura J, Chimenti S, Limana F, Jakoniuk I, Quaini F, Nadal-Ginard B, Bodine DM, Leri A, Anversa P: Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci USA (2001) 98(18):10344-10349.
33. Iwanaga K, Takano H, Ohtsuka M, Hasegawa H, Zou Y, Qin Y, Odaka K, Hiroshima K, Tadokoro H, Komuro I: Effects of G-CSF on cardiac remodeling after acute myocardial infarction in swine. Biochem Biophys Res Commun (2004) 325(4):1353-1359.
34. Hasegawa H, Takano H, Iwanaga K, Ohtsuka M, Qin Y, Niitsuma Y, Ueda K, Toyoda T, Tadokoro H, Komuro I: Cardioprotective effects of granulocyte colony-stimulating factor in swine with chronic myocardial ischemia. J Am Coll Cardiol (2006) 47(4):842-849.
35. Askari AT, Unzek S, Popovic ZB, Goldman CK, Forudi F, Kiedrowski M, Rovner A, Ellis SG, Thomas JD, DiCorleto PE, Topol EJ, Penn MS: Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet (2003) 362(9385):697-703.
36. Kang HJ, Kim HS, Zhang SY, Park KW, Cho HJ, Koo BK, Kim YJ, Soo LD, Sohn DW, Han KS, Oh BS et al: Effects of intracoronary infusion of peripheral blood stem-cells mobillsed with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: The MAGIC cell randomised clinical trial. Lancet (2004) 363(9411):751-756.
37. Valgimigli M, Rigolin GM, Cittantii C, Malagutti P, Curello S, Percoco G, Bugli AM, Della Porta M, Bragotti LZ, Ansani L, Mauro E et al: Use of granulocyte-colony stimulating factor during acute myocardial infarction to enhance bone marrow stem cell mobilization in humans: Clinical and angiographic safety profile. Eur Heart J (2005) 26(18):1838-1845.
38. Ince H, Petzsch M, Kleine H, Schmidt H, Rehders T, Körber T, Schümichen C, Freund M, Nienaber CA: Preservation from left ventricular remodeling by front-integrated revascularization and stem cell liberation in evolving acute myocardial infarction by use of granulocyte-colony-stimulating factor (FIRSTLINE-AMI). Circulation (2005) 112(20):3097-3106.
39. Zohinhofer D, Ott I, Mehilli J, Schomig K, Michalk F, Ibrahim T, Meisetschlager G, von Wedel J, Bollwein H, Seyfarth M, Dirschinger J et al: Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: A randomized controlled trial. J Am Med Assoc (2006) 295(9):1003-1010.
40. Ripa RS, Jorgensen E, Wang Y, Thune JJ, Nilsson JC, Sondergaard L, Johnsen HE, Kober L, Grande P, Kastrup J: Stem cell mobilization induced by subcutaneous granulocyte-colony stimulating factor to improve cardiac regeneration after acute ST-elevation myocardial infarction: Result of the double-blind, randomized, placebo-controlled stem cells in myocardial infarction (STEMMI) trial. Circulation (2006) 113(16):1983-1992.
41. Boyle AJ, Whitbourn R, Schlicht S, Krum H, Kocher A, Nandurkar H, Bergmann S, Daniell M, O'Day J, Skerrett D, Haylock D et al: Intra-coronary high-dose CD34+ stem cells in patients with chronic ischemic heart disease: A 12-month follow-up. Int J Cardiol (2006) 109(1):21-27.
42. Archundia A, Aceves JL, López-Hernández M, Alvarado M, Rodriguez E, Diaz Quiroz G, Paez A, Rojas FM, Montano LF: Direct cardiac injection of G-CSF mobilized bone-marrow stem-cells improves ventricular function in old myocardial infarction. Life Sci (2005) 78(3):279-283.
43. Huttmann A, Duhrsen U, Stypmann J, Noppeney R, Nuckel H, Neumann T, Gutersohn A, Nikol S, Erbel R: Granulocyte colony-stimulating factor-induced blood stem cell mobillsation in patients with chronic heart failure - feasibility, safety and effects on exercise tolerance and cardiac function. Basic Res Cardiol (2006) 101(1):78-86.
44. Amgen Inc: Neupogen® (Filgrastim). Press Release (2004): December 20. http://www.neupogen.com/pdf/Neupogen_Pl.pdf
45. Takano H, Qin Y, Hasegawa H, Ueda K, Niitsuma Y, Ohtsuka M, Komuro I: Effects of G-CSF on left ventricular remodeling and heart failure after acute myocardial infarction. J Mol Med (2006) 84(3):185-193.
46. Takahama H, Minamino T, Hirata A, Ogai A, Asanuma H, Fujita M, Wakeno M, Tsukamoto O, Okada K, Komamura K, Takashima S et al: Granulocyte colony-stimulating factor mediates cardioprotection against ischemia/ reperfusion injury via phosphatidylinositol-3-kinase/Akt pathway in canine hearts. Cardiovasc Drugs Ther (2006) 20(3):159-165.
47. Werner N, Nickenig G, Laufs U: Pleiotropic effects of HMG-CoA reductase inhibitors. Basic Res Cardiol (2002) 97(2):105-116.
48. Vasa M, Fichtlscherer S, Adler K, Aicher A, Martin H, Zeiher AM, Dimmeler S: Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation (2001) 103(24):2885-2890.
49. Walter DH, Dimmeler S, Zeiher AM: Effects of statins on endothelium and endothelial progenitor cell recruitment. Semin Vasc Med (2004) 4(4):385-393.
50. Spyridopoulos I, Haendeler J, Urbich C, Brummendorf TH, Oh H, Schneider MD, Zeiher AM, Dimmeler S: Statins enhance migratory capacity by upregulation of the telomere repea-binding factor TRF2 in endothelial progenitor cells. Circulation (2004) 110(19):3136-3142.
51. Horwich TB, MacLellan WR, Fonarow GC: Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol (2004) 43(4):642-648.
52. Laufs U, Custodis F, Bohm M: HMG-CoA reductase inhibitors in chronic heart failure: Potential mechanisms of benefit and risk. Drugs (2006) 66(2):145-154.
53. De Clercq E: The bicyclam AMD-3100 story. Nat Rev Drug Discov (2003) 2(7):581-587.
54. Kilby JM: Therapeutic potential of blocking HIV entry into cells: Focus on membrane fusion inhibitors. Expert Opin Investig Drugs (1999) 8(8):1157-1170.
55. Larochelle A, Krouse A, Metzger M, Orlic D, Donahue RE, Fricker S, Bridger G, Dunbar CE, Hematti P: AMD-3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. Blood (2006) 107(9):3772-3778.
56. Flomenberg N, Devine SM, Dipersio JF, Liesveld JL, McCarty JM, Rowley SD, Vesole DH, Badel K, Calandra G: The use of AMD-3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood (2005) 106(5):1867-1874.
57. Abbott JD, Huang Y, Liu D, Hickey R, Krause DS, Giordano FJ: Stromal cell-derived factor-1α plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury. Circulation (2004) 110(21):3300-3305.
58. Iwakura A, Luedemann C, Kusano K, Takenaka H, Eaton E, Bridger G, Losordo DW: AMD-3100, a CXCR4 antagonist, augments incorporation of bone marrow-derived endothelial progenitor cells into sites of myocardial revascularization. Circulation (2003) 108(17) Suppl IV: 159.